62 phenotypes from 5 alleles in 6 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Abhd5tm1.1Lqyu/Abhd5tm1.1Lqyu Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * DBA	abnormal hepatocyte morphology	J:199570
	abnormal lipid level	J:199570
	abnormal liver morphology	J:199570
	abnormal liver physiology	J:199570
	abnormal phospholipid level	J:199570
	decreased fatty acid oxidation	J:199570
	decreased triglyceride lipase activity	J:199570
	enlarged liver	J:199570
	hepatic steatosis	J:199570
	normal homeostasis/metabolism phenotype	J:199570
	increased circulating alanine transaminase level	J:199570
	increased circulating aspartate transaminase level	J:199570
	increased liver cholesterol level	J:199570
	increased liver free fatty acids level	J:199570
	increased liver triglyceride level	J:199570
	increased liver weight	J:199570
	liver fibrosis	J:199570
	liver inflammation	J:199570
	macrovesicular hepatic steatosis	J:199570
	microvesicular hepatic steatosis	J:199570
	oxidative stress	J:199570
	pale liver	J:199570
Abhd5tm1.1Rze/Abhd5tm1.1Rze involves: 129P2/OlaHsd * C57BL/6	abnormal granulocyte morphology	J:160725
	abnormal keratinocyte differentiation	J:160725
	abnormal lipid homeostasis	J:160725
	abnormal lipid level	J:160725
	abnormal skin development	J:160725
	abnormal skin physiology	J:160725
	decreased birth body size	J:160725
	decreased birth weight	J:160725
	decreased body length	J:160725
	decreased circulating glucose level	J:160725
	decreased circulating triglyceride level	J:160725
	decreased fatty acids level	J:160725
	decreased triglyceride lipase activity	J:160725
	epidermis stratum spinosum hyperplasia	J:160725
	hepatic steatosis	J:160725
	hyperkeratosis	J:160725
	impaired lipolysis	J:160725
	impaired skin barrier function	J:160725
	increased liver triglyceride level	J:160725
	increased triglyceride level	J:160725
	neonatal lethality	J:160725
Abhd5tm1a(KOMP)Wtsi/Abhd5tm1a(KOMP)Wtsi B6JTyr;B6N-Abhd5tm1a(KOMP)Wtsi/Wtsi	abnormal maxilla morphology	J:165965
	decreased body weight	J:165965, J:175295
Abhd5tm1a(KOMP)Wtsi/Abhd5tm1a(KOMP)Wtsi involves: C57BL/6 * C57BL/6N	abnormal Sertoli cell morphology	J:213427
	decreased bone trabecula number	J:213427
	increased trabecular bone thickness	J:213427
Abhd5tm1Murm/Abhd5tm1Murm B6.129S-Abhd5tm1Murm	abnormal ceramide level	J:240682
	increased triglyceride level	J:240682
Abhd5tm1Rze/Abhd5tm1Rze Tg(Ckmm-cre)5Khn/0 involves: 129P2/OlaHsd * C57BL/6 * FVB	abnormal glucose homeostasis	J:197835
	abnormal heart left ventricle morphology	J:197835
	abnormal lipid homeostasis	J:197835
	decreased circulating free fatty acids level	J:197835
	decreased circulating glucose level	J:197835
	decreased circulating insulin level	J:197835
	decreased circulating triglyceride level	J:197835
	decreased lipoprotein lipase activity	J:197835
	decreased liver triglyceride level	J:197835
	decreased oxygen consumption	J:197835
	decreased ventricle muscle contractility	J:197835
	normal homeostasis/metabolism phenotype	J:197835
	impaired lipolysis	J:197835
	improved glucose tolerance	J:197835
	increased cardiac muscle cell glucose uptake	J:197835
	increased cardiac muscle triglyceride level	J:197835
	increased heart left ventricle weight	J:197835
	increased heart weight	J:197835
	increased respiratory quotient	J:197835
	increased skeletal muscle triglyceride level	J:197835
	myocardium steatosis	J:197835
	premature death	J:197835